Furthermore, we conducted GO analysis using previously reported global proteomic and phosphoproteomic data from FLT3 wild-type R/R AML [28], pediatric/adult R/R AML [29], and FLT3 wild-type [30] patient-derived samples (Supplementary Data File 6 and Fig. S4D–G). This evidence concerns the gene FLT3 and acute myeloid leukemia.